10-Year Free Cash Flow Projections(showing years 1, 3, 5, 7, 10)
| Year | Year 1 | Year 3 | Year 5 | Year 7 | Year 10 |
|---|
| Revenue | $3.2B | $3.7B | $4.0B | $4.2B | $4.6B |
| EBIT | $743M | $844M | $921M | $969M | $1.1B |
| Tax | $147M | $167M | $182M | $192M | $209M |
| NOPAT | $596M | $677M | $739M | $778M | $847M |
| + Depreciation | $149M | $169M | $184M | $194M | $211M |
| - Capex | $330M | $321M | $290M | $243M | $162M |
| - Δ NWC | $31M | $44M | $17M | $20M | $24M |
| Free Cash Flow | $383M | $482M | $616M | $710M | $873M |
| Discount Factor | 0.912 | 0.758 | 0.631 | 0.524 | 0.398 |
| Present Value | $349M | $366M | $388M | $372M | $347M |
FCF Formula: Free Cash Flow = NOPAT + Depreciation - Capex - Change in Net Working Capital
Sensitivity AnalysisPrice per Share
| WACC ↓ / Growth → | 2.00% | 2.50% | 3.00% | 3.50% | 4.00% |
|---|
| 7.66% | $213.80 | $219.12 | $225.59 | $233.61 | $243.82 |
| 8.66% | $190.38 | $193.86 | $197.96 | $202.86 | $208.81 |
| 9.66% | $171.39 | $173.79 | $176.55 | $179.76 | $183.54 |
| 10.66% | $155.54 | $157.26 | $159.20 | $161.41 | $163.96 |
| 11.66% | $142.03 | $143.29 | $144.70 | $146.29 | $148.08 |
How to read: This table shows how the valuation changes with different WACC (discount rate) and terminal growth rate assumptions. Green = undervalued, Red = overvalued.
Key Assumptions & Drivers✓ Using Analyst Consensus Estimates• Healthcare Sector
Growth Assumptions (Select Years)
Year 1 Revenue Growth5.68%
Year 3 Revenue Growth6.99%
Year 5 Revenue Growth2.44%
Year 7 Revenue Growth2.67%
Year 10 Revenue Growth3.00%
Terminal Growth Rate3.00%
Margin & Efficiency
Current EBIT Margin22.87%
Tax Rate19.76%
Historical Capex / Rev10.17%
Terminal Capex / Rev3.50%
NWC / Revenue18.05%
Key Drivers: Revenue growth, operating margin expansion, capex efficiency, and working capital management are the primary drivers of cash flow generation. Terminal value assumptions significantly impact final valuation.
Institutional-Grade Methodology
Actual Company Data: Revenue, EBIT, Capex, NWC, Tax Rate, Interest Expense, Beta
Market Assumptions: Risk-free: 4.5% (10Y), MRP: 4.5% (Damodaran 2026), Exit: 24x EV/EBITDA (Healthcare sector)
This DCF model is for informational purposes only. Projections are based on assumptions that may not materialize. Past performance does not guarantee future results. Consult a financial advisor before making investment decisions.